Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2~* Participant has relapsed/refractory disease (received at least 1 prior therapy)~* Participant has diagnosis of CLL that meets published 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute Working Group (IWCLL NCI-WG) Guidelines and:~  * has an indication for treatment according to the 2008 Modified IWCLL NCI-WG criteria~ * has clinically measurable disease (lymphocytosis greater than 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)~* In addition, participants:~  * with or without 17p deletion or TP53 mutation, assessed by a local laboratory in bone marrow or peripheral blood are eligible~ * may have been previously treated with a prior B-cell receptor inhibitor~* Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory at Screening~Exclusion Criteria:~* Participant has developed Richter's transformation or Prolymphocytic leukemia~* Participant has previously received venetoclax~* History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:~  * adequately treated in situ carcinoma of the cervix uteri~ * adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin~ * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent~* Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose corticosteroids~* Participant has undergone an allogeneic stem cell transplant~* Treatment with any of the following within five half-lives or 14 days (if half-life unknown) as applicable prior to the first dose of venetoclax, or clinically significant adverse effect(s)/toxicity(s) of the previous therapy have not resolved to \< National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Grade 2:~  * Any anti-cancer therapy including chemotherapy, or radiotherapy;~ * Investigational therapy, including targeted small molecule agents~* Participant is human immunodeficiency virus (HIV) positive~* Participant has known allergy to both xanthine oxidase inhibitors and rasburicase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Venetoclax (Type: EXPERIMENTAL): Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, plus one additional year until the venetoclax extension study was open, determined on a case by case basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).